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Abstract
Background: Angiogenesis, or the remodeling of existing vasculature serves as a lifeline to nourish
developing embryos and starved tissues, and to accelerate wound healing, diabetic retinopathy, and
tumor progression. Recent studies indicate that angiogenesis requires growth factor activity as well
as cell adhesion events mediated by α5β1 and αvβ3 integrins. We previously demonstrated that
human lipid phosphate phosphohydrolase-3 (LPP3) acts as a cell-associated ligand for α5β1 and αvβ3
integrins. Here, we test the hypothesis that an anti-LPP3 antibody can inhibit basic fibroblast growth
factor (bFGF)-and vascular endothelial growth factor (VEGF)-induced capillary morphogenesis of
endothelial cells (ECs).
Results:  We report that bFGF and VEGF up-regulate LPP3 protein expression in ECs.
Immunoprecipitation analyses show that LPP3 is a cell surface protein and undergoes N-
glycosylation. Fluorescent activated cell sorting (FACS) data suggest that anti-LPP3-RGD detects
native neoepitope on the surface of activated ECs. Moreover, we demonstrate LPP3 protein
expression in tumor endothelium alongside VEGF. The embedding of ECs into three-dimensional
type I collagen in the presence of bFGF and VEGF induce capillary formation. Importantly, we show
that the addition of an anti-LPP3 antibody specifically and significantly blocks bFGF- and VEGF-
induced capillary morphogenesis of ECs.
Conclusion: These data suggest that activated ECs as well as tumor endothelium express LPP3
protein. In an in vitro assay, the anti-LPP3-RGD specifically blocks bFGF and VEGF induced capillary
morphogenesis of ECs. Our results, therefore, suggest a role for LPP3 in angiogenesis.
Background
Angiogenesis, the sprouting or remodeling of preexisting
quiescent blood vessels, is critical for embryonic develop-
ment, wound healing, and various pathological condi-
tions such as tumor progression, complications associated
with acquired immune deficiency syndrome (AIDS),
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rheumatoid arthritis, and diabetic retinopathy [1-4]. Ang-
iogenesis can be initiated by hypoxic tumors, inflamma-
tion or an increased accumulation of pro-angiogenic
factors. These factors, in turn, trigger secretion of matrix
metalloproteinases (MMPs) that dissolve the basement
membrane. This MMP-mediated membrane dissolution is
an essential event for subsequent EC activation, migra-
tion, and capillary formation [1-6]. Angiogenesis is regu-
lated through a dynamic balance between pro- and anti-
angiogenic factors [1-4]. Angiogenic mediators include
growth factors such as basic fibroblast growth factor
(bFGF), vascular endothelial growth factor (VEGF), colla-
gen and fibronectin, and proteases such as MMPs [2,4,6-
8]. VEGF signaling activates ECs through VEGF receptor-1
(VEGFR-1, also known as Flt) and VEGFR2 (KDR/Flk-1)
tyrosine kinase receptors, and promotes cell migration,
survival, proliferation and differentiation [5,6,9]. The
microenvironment surrounding a tumor is generally rich
in VEGF, which is upregulated in response to hypoxia and
can directly activate ECs to initiate tumor angiogenesis,
growth and metastatic deposits [1-4,9]. Both bFGF and
VEGF are able to induce tumor angiogenesis and wound
healing, as well as contribute to unwanted angiogenesis
[2,4-6,9]. Addition of bFGF and VEGF can increase the
expression of EC integrins, a family of cell surface recep-
tors that regulate cell adhesion events [2,10-13]. In partic-
ular, α5β1 and αvβ3 integrins mediate adhesion, migration,
and proliferation of endothelial cells by interacting with
extracellular matrix (ECM) proteins such as fibronectin,
fibrin, and vitronectin [13-15]. In addition, integrins also
mediate cell-cell interactions by associating with counter-
receptors or cell associated integrin ligands [16,17]; such
interactions generate both chemical and mechanical sig-
nals that influence cellular behavior [18-22].
Our ability to target neo-epitopes expressed by tumor-
endothelium could potentially minimize the toxicity and
drug-resistance associated with conventional chemother-
apy treatment of solid tumors [9]. Recently, we identified
lipid phosphate phosphohydrolase-3 (LPP3), also called
phosphatidic acid phosphatase-2b (PAP2b), VEGF and
type I collagen inducible protein (VCIP) in a functional
assay of angiogenesis [23,24]. Lipid phosphate phospho-
hydrolases (LPPs) dephosphorylate polar lipid signaling
molecules, both within and outside cells [25-27]. Struc-
turally, all LPPs display a 6-transmembrane channel-like
organization [29-32]. Both the N-and C-terminal seg-
ments are located in the cytoplasm [32,33]. There are
three extracellular loops, and the proposed 2nd extracellu-
lar loop of LPP3 contains a lipid phosphatase, one cell-
adhesion motif, and a N-glycosylation site [23,29,32,33].
LPP3 protein has been identified within intracellular
organelles as well as on the cell surface, and in both loca-
tions it exhibits ectoenzyme activity [29-32]. Previously
we have shown that LPP3-RGD (RGE in mice) can act as a
cell-associated integrin ligand and mediate cell-cell inter-
actions [23,28]. Consistent with our findings, confocal
image analyses demonstrated that green fluorescent pro-
tein-LPPl remains apically sorted, whereas green fluores-
cent protein-LPP3 co-localized with E-cadherin in cell-cell
junctions and the basolateral domains of polarized
MDCK cells [23,33]. Transfection of mutants as well as
swapping experiments have established that LPP1 protein
contains an apical targeting signal sequence (FDKTRL) in
its N-terminal segment; in contrast, LPP3 protein contains
dityrosine (109Y/110Y) cell-cell and basolateral sorting
motifs [33]. Unlike Lpp2, whose function is dispensable
for embryonic development, Lpp3 is required for extra-
embryonic vasculogenesis and axis patterning [34,35],
raising the possibility that the function of the LPP3 pro-
tein may also be to mediate adult, as well as pathological,
angiogenesis.
We previously showed that anti-LPP3-RGD blocks cell
aggregation (cell-cell interactions) that is mediated by
α5β1 and  αvβ3 integrins [23]. In the current study, we
examine whether an anti-LPP3-RGD antibody can inhibit
bFGF- and VEGF-mediated capillary morphogenesis of
ECs. In this study, we demonstrate that the addition of
bFGF and VEGF angiogenic cytokines stimulate the
expression of LPP3 protein of ECs. We further show that
tumor endothelium express LPP3 protein. By embedding
ECs in a three-dimensional type I collagen matrix fol-
lowed by treatment with bFGF and VEGF to induce forma-
tion of capillaries, we demonstrate the ability of anti-LPP3
antibodies to inhibit bFGF- and VEGF-induced capillary
morphogenesis. These findings are the first to our knowl-
edge to suggest a mechanism by which anti-LPP3-RGD
antibodies may inhibit capillary morphogenesis of ECs.
Results
Basic FGF and VEGF induce expression of LPP3 in HUVECs
Hypoxic tumors in vivo and many cell lines in vitro secrete
bFGF and VEGF. Both bFGF and VEGF are components of
the tumor microenvironment capable of activating ECs.
To evaluate the potential role of LPP3 in angiogenesis, we
investigated the effects of treatment of HUVECs with
VEGF and bFGF. We stimulated monolayer HUVECs with
either VEGF165 or bFGF for various time periods between
0 and 18 h, and subjected lysates to Western blot analyses
using an affinity purified anti-LPP3-cyto antibody (Fig.
1A). The expression of LPP3 protein levels was increased
by >3-fold in response to VEGF165 treatment (100 ng/ml)
for 6 or 12 h (relative to control levels), whereas bFGF (20
ng/ml) had a significantly less robust effect on LPP3 levels
during the same treatment duration (Fig. 1A). The concen-
trations of VEGF165 and bFGF used in this experiment
were optimal as evidenced by the observation that both
factors activated extracellular-signal-regulated kinase
(Erkl/2) in these cells in an independent experiment (dataCell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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not shown). We observed that anti-LPP3-c-cyto antibody
detects three major polypeptides, two of which (~52 and
~46 kDa) are slow and one (~36 kDa) that exhibits high
mobility (Fig. 1A). Since, LPP3 contains a single consen-
sus N-glycosylation site (170N) on the proposed 2nd extra-
cellular loop of the LPP3 protein, the high mobility anti-
LPP3-c-cyto immunoreactive species is likely to be a post-
translationally modified form. This idea is actually sup-
ported by our data with N-glycanase described elsewhere.
As a positive control for the cytokines used, the mem-
brane was stripped and re-blotted with an anti-proliferat-
ing cell nuclear antigen (PCNA) antibody (Fig. 1B). As
expected, both cytokines increased PCNA expression to
optimal levels. The level of Focal adhesion kinase (Fak)
protein was measured to confirm equivalent protein load-
ing (Fig. 1C).
Expression of LPP3 protein in monolayer ECs Figure 1
Expression of LPP3 protein in monolayer ECs. Confluent ECs (passage 4) were starved for 6 h in conditioned medium 
(M199 supplemented with 0.2% BSA + 1× ITS), and then stimulated with VEGF165 (100 ng/ml) or bFGF (20 ng/ml) for various 
durations, as indicated. Cells were solubilized, clarified by centrifugation, and the protein concentrations were determined. 
Samples were subjected to SDS-PAGE and analyzed by immunoblotting with: (A) Rabbit anti-LPP3-c-cyto polyclonal antibody 
(2.0 µg/ml). Anti-LPP3-c-cyto antibody detects unprocessed LPP3 protein that appears as ~36 kDa, and two major polypep-
tides migrate below the ~52 kDa molecular weight marker, LPP3 polypeptides are indicated by arrowheads; (B) Anti-PCNA 
monoclonal antibody (0.5 µg/ml). (C) Anti-Fak monoclonal antibody (1.0 µg/ml). (D) Cell surface biotinylation of intact 
cells and immunoprecipitation analysis. K562 (lane 1, unstimulated), HUVECs (lane 2, stimulated with VEGF, 100 ng/ml 6 
hours), and HUVECs (lane 3, stimulated with bFGF, 20 ng/ml for 6 h) subjected to cell surface biotinylation, lysed in RIPA 
buffer, clarified by centrifugation and immunoprecipitated using anti-LPP3-c-cyto (5 µg) antibody. Immunocomplexes were 
resolved by 10% SDS-PAGE under reducing condition and analyzed by ligand blotting with streptavidin-HRP (1:10000). Data 
shown are representative of those obtained in at least three separate experiments, with similar results. (E) De-N-glycosyla-
tion of LPP3 protein. Monolayer HUVECs (passage 4) were stimulated with VEGF165 for 6 h and subjected to cell surface 
biotinylation, lysed in RIPA buffer, clarified by centrifugation, and immunoprecipitated by either rabbit IgG (control) or anti-
LPP3-c-cyto antibodies, as indicated. Following immunoprecipitation with anti-LPP3-c-cyto antibodies, the contents were 
equally divided into two tubes. One tube was left untreated, and the second tube treated with N-Glyganase (50 units of 
PNGaseF) enzyme at 37°C for 3 h. Immunocomplexes were analyzed by ligand blotting with streptavidin-HRP (1:10000). 
Arrowheads indicate LPP3 polypeptides. Arrows indicate unknown polypeptides. Molecular weights are given in kiloDaltons 
(kDa). Data shown are representative of those obtained in at least three separate experiments, with similar results.Cell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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Next, to determine the ability of anti-LPP3-c-cyto anti-
body to immunoprecipitate LLP3 antigen, we used ECs
and human erythroleukemia (K562) cells (Fig. 1D). K562
cells that do not express LPP3 protein was included as a
negative control. K562 cells were left unstimulated (Fig.
1D, lane 1), while ECs were stimulated with VEGF (Fig.
1D, lane 2) and bFGF (Fig. 1D, lane 3), and subsequently
subjected to cell surface biotinylation and immunoprecip-
itation with an anti-LPP3-c-cyto antibody and analyzed by
ligand blotting with Streptavidin-HRP (Fig. 1D). We
found that the anti-LPP3-c-cyto did not immunoprecipi-
tate 36–52 kDa polypeptides from K562 cells (negative
control cell line); in contrast, ligand blotting with strepta-
vidin-HRP detected three major polypeptides (36, 42 and
52 kDa, indicated by arrows) (Fig. 1D). These data suggest
that the LPP3 antigen is exposed on the extracellular sur-
face of ECs and can be immunoprecipitated by an anti-
LPP3-c-cyto antibody.
LPP3 contains a single N-glycosylation site (170N, acces-
sion number O14495) [23]. Several pilot experiments
suggested that, depending upon how cells are cultured,
the variation in the extent of LPP3 glycosylation can be
complex and dramatic. To examine this possibility, we
prepared cell extracts from ECs and subjected lysates to
immunoprecipitation as indicated (Fig. 1E). After several
washes with cell lysis buffer, immunoprecipitates were
incubated with N-glycanase F (PNGaseF), an enzyme that
cleaves the carbohydrate moiety. In doing so, we observed
that most of the slow mobility (smeared) polypeptides
disappeared, leaving behind a ~36 kDa unprocessed
polypeptide (Fig. 1E). Consistent with previous reports,
we observed that LPP3 is N-glycosylated [30,31], and the
extent of N-glycosylation appears to be cell type- and cul-
ture condition-dependent.
The LPP3 is a cell surface antigen
Anti-LPP3-RGD antibody was raised by injecting rabbit
with a synthetic peptide modeled after the proposed 2nd
extracellular loop of LPP3 protein (EGY-
IQNYRCRGDDSKVQEAR) [23]. Previously we relied on
the specificity of the anti-LPP3-RGD antibody to analyze
tumor sections and inhibit LPP3-mediated cell-cell inter-
actions [23]. In the current study, we determined the abil-
ity of anti-LPP3-RGD to detect native LPP3 antigen of
intact ECs. Towards this end, ECs were either left unstim-
ulated or were stimulated with VEGF, incubated with anti-
LPP3-RGD and subjected to fluorescence activated cell
sorting (FACS). In contrast to unstimulated ECs that do
not express LPP3 protein significantly, the addition of
VEGF induced cell surface expression of LPP3 protein of
monolayer ECs (Fig. 2A). This result indicates that VEGF
stimulates expression of LPP3 antigen on the surface of
ECs, which can be detected by anti-LPP3-RGD antibody.
This data also suggests that anti-LPP3-RGD antibody
detects intact and native LPP3 antigen neoepitope
expressed by activated ECs. A schematic diagram showing
topological and structural organization of LPP3 is shown
(Fig. 2B).
Tumor endothelium expresses LPP3 protein
It is apparently clear that the tumor microenvironment
contains bFGF and VEGF. Because bFGF and VEGF induce
LPP3 expression in cultured ECs, we hypothesized that
LPP3 protein might be similarly expressed by tumor-
endothelium. To examine this hypothesis, serial angioma
and hemangioma sections were subjected to immunos-
taining with anti-Flk-1, anti-PECAM-1 (CD31), and von
Willebrand factor (vWF) to establish the presence of ECs
and blood vessels as previously described [23]. We have
previously shown that quiescent skin blood vessels are
negative for anti-LPP3-RGD immunoreactivity [please see
reference 23 for online supplemental data]. Hypoxic tis-
sues as well as inflamed tissues are known to express VEGF
[1,4]. Consistent with these reports, our data indicate that
VEGF (green) is diffusedly distributed throughout angi-
oma and hemangioma tissues, with significantly higher
expression in the blood vessels (Fig. 3B,3E,3H). As shown
in Fig. 3A,3D and 3G, LPP3 (red) protein appears to co-
localize with VEGF in the angioma, including in the
endothelium where the yellow ring like structure indicates
colocalization; however, their molecular proximity
remains unknown. Similarly, the expression of LPP3 pro-
tein was coincident with VEGF expression in the heman-
gioma section examined (Fig. 3G,3H,3I). These data
demonstrate that both LPP3 and VEGF are diffusedly dis-
tributed within tumor vasculature, and LPP3 expression
may not be exclusively restricted to ECs. Incubation of the
antibodies with peptides that had been used to generate
the primary antibody blocked immunoreactivity, con-
firming the specificity of antibodies used, as previously
described [23]. This data is consistent with our earlier
observation that the LPP3 protein is highly expressed in
tumor endothelium [23].
Inhibition of bFGF and VEGF induced capillaries by anti-
LPP3-RGD antibodies
A considerable number of studies indicate that bFGF- and
VEGF-mediated signaling, as well as cell adhesion events
mediated by α5β1 and αvβ3 integrins, critically determine
the outcome of angiogenesis. Because the LPP3-RGD pro-
tein acts as a cell-associated integrin ligand for α5β1 and
αvβ3 integrins, we hypothesized that an anti-LPP3-RGD
antibody could inhibit cell-cell interactions that may
impede the ability of ECs to undergo capillary morpho-
genesis (also called tubulogenesis). To evaluate the capac-
ity of anti-LPP3-RGD to block capillary morphogenesis of
ECs, we employed early passage (between 3–4 total) ECs.
Typically, we embed ECs between two layers of type I col-
lagen matrices, and treat them with bFGF and VEGF in theCell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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LPP3 is a cell surface antigen Figure 2
LPP3 is a cell surface antigen. A) HUVECs (passage 4) were serum-starved for 6 h, thereafter, left untreated (-) or treated 
with VEGF165 (100 ng/ml) for 6 h and subjected to fluorescent activated cell sorting (FACS) using indicated antibodies. B) Sche-
matic representation of human LPP3 protein showing 6-transmembrane organization. Proposed 3 extracellular loops (L-l, -2, 
and -3) are as shown. One lipid phosphatase motif, a cell adhesion sequence, a putative proton donor sequence and a dityro-
sine basolateral targeting sequence are as shown. Both N-and C-terminals of LPP3 protein are located inside the cytoplasm.Cell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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presence of 20% serum. As previously described, the proc-
ess of capillary formation by ECs in a three-dimensional
type I collagen take place over a period of 24 to 72 h, and
requires the addition of bFGF and VEGF [23,24].
For the purpose of this study, capillaries formed after 24 h
of culture in 3D collagen were considered "pre-formed
vessels", whereas capillaries formed after more than 24 h
of culture were considered "new capillaries". We used
affinity purified rabbit anti-IgG (control) polyclonal anti-
bodies (pAbs) and mouse anti-MHC class II (W6/32)
monoclonal Abs (mAbs), and mouse anti-β1 (4B4) and
anti-αvβ3 (LM609) mAbs, as negative and positive con-
trols, respectively.
In the absence of antibodies, we observed an increased
number of capillaries formed from 36 to 72 h in culture
(Fig. 4, filled black bar). The addition of an anti-MHC
mAb (empty bar) and rabbit IgG (filled blue bar) resulted
in minimal inhibition, and for the purpose of our study
we consider these minimal inhibitions as baseline (Fig.
4). In contrast, the addition of the anti-β1 (filled red bar)
and anti-αvβ3 (filled green) mAbs caused regression of the
pre-formed capillaries (Fig. 4). Anti-αvβ3 mAbs reduced
the number of pre-formed capillaries by more than 50%,
suggesting that other cell surface proteins, such as
fibronectin-binding integrin α5β1 and collagen/laminin
binding integrins may also mediate capillary morphogen-
esis. Indeed, anti-β1 integrin subunit mAbs inhibited pre-
formed interconnections and reduced the number of cap-
illaries by ~60–70% (Fig. 4). No two mAbs were added
simultaneously since it has been reported that α5β1 and
αvβ3 integrin antibodies together induce complete col-
lapse and regression of tubules in vitro [37,38]. Unexpect-
edly, the addition of the anti-LPP3-RGD antibody (filled
yellow bar) had a dramatic effect on bFGF and VEGF-
induced capillary formation (Fig. 4). The effect of anti-
LPP3-RGD was comparable to anti-αvβ3 mAbs (Fig. 4,
solid yellow bar). Representative cross sections of 3D gel
are shown (Fig. 5). Arrows indicate lumen like structures.
These data suggest that antibodies affecting cell adhesion,
migration and cell-cell interaction events inhibit capillary
morphogenesis by ECs in vitro. These data demonstrate
that an affinity-purified rabbit anti-LPP3-RGD polyclonal
antibody can inhibit bFGF- and VEGF-induced capillary
formation in vitro.
Discussion
We previously identified LPP3 in a functional assay of
angiogenesis and reported that human LPP3 protein
mediates cell-cell interactions [23,24]. Although the pro-
posed cell adhesion sequences of human (RGD) and
mouse (RGE) LPP3 are not identical, we observed that, in
response to long-term cell adhesion, both sequences effi-
ciently ligate α5β1 and αvβ3 integrins, and these adhesion
events do not require protein synthesis [28]. Many previ-
ous studies have described a correlation between over-
expression of LPP3 as an enzyme and down-regulation of
cell signaling. However, the critical importance of Lpp3
gene function during developmental angiogenesis is
underscored by the observation that mice embryos lack-
ing Lpp3 die at day E7.5 due to a dearth of functional
Tumor endothelium express LPP3 protein alongside VEGF Figure 3
Tumor endothelium express LPP3 protein alongside 
VEGF. Paraffin-embedded angioma (A-C) and hemangioma 
(D-I) tumor tissue sections (4 µm) were subjected to anti-
gen retrieval, and sequentially incubated with the indicated 
antibodies. After washing with PBS, sections were incubated 
with donkey anti-goat/rabbit IgG conjugated to Texas-red 
(red) and goat anti-mouse IgG conjugated to FITC (green). C, 
F, and I images represent overlays of A, B; D, E; and G, H 
respectively. Images were captured below saturation level. 
Merged yellow represents co-expression. Data shown are 
representative of those obtained in at least three separate 
experiments, with similar results. (L, lumen; Magnification, 
100×; Bars, 50 µM).Cell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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vasculature [35]. This report suggested that LPP3 protein
regulates cellular interactions [35]. It is clear that further
investigation will be necessary to elucidate the function of
LPP3. Regardless of the mechanism, LPP3 is likely to be
required during both adult and pathological angiogen-
esis. Therefore, we hypothesize that inhibition of LPP3
protein function blocks angiogenesis. Here, we asked the
question whether an anti-LPP3-RGD antibody inhibits
bFGF and VEGF induced capillary morphogenesis of ECs.
Indeed, we found evidence that an anti-LPP3-RGD anti-
body can inhibit capillary morphogenesis of ECs.
It has become increasingly clear that bFGF- and VEGF-
induced angiogenesis requires integrin-mediated adhe-
sion events, a process by which ECs maintain cell-cell con-
tact, survive, migrate, and proliferate [11-14,17]. ECs are
known to express α2β1, α3β1, α5β1, α6β1, αvβ3 and  αvβ5,
integrins [13,17,18]. Several integrins have been sug-
gested to play a role in each step of these processes; of
these, α5β1 and αvβ3 integrins appear to be key players [11-
14]. Previously, we provided evidence that a subset of
integrins, including α1β1, α5β1 and αvβ3 are able to pro-
mote the EC cell cycle progression through the Shc path-
way [17,18,21]. In vitro and in vivo assays have provided
evidence that interference with the function of α5β1 and
αvβ3 integrins block bFGF- and VEGF-induced angiogen-
esis, suggesting that α5β1- and αvβ3-mediated signaling
networks cooperate by regulating a similar angiogenic sig-
naling cascade [39-42]. Because signaling from α5β1 and
αvβ3  integrins are critical for EC functioning, perhaps
depriving LPP3-mediated cell-cell interactions interrupts
several important signaling pathways, thereby inducing
regression of capillary morphogenesis by ECs.
Our data indicate that pathophysiologically relevant ago-
nists, e.g. bFGF and VEGF cytokines, can stimulate the
expression of LPP3 protein in ECs. These data imply that
LPP3 protein expression is likely to be associated with
inflamed tissues and organs that require angiogenesis. We
also demonstrate that LPP3 protein is up-regulated in
tumor endothelium. We also show the ability of anti-
LPP3-RGD to detect native LPP3 antigen on the cell sur-
face of ECs. Considering the ability of Lpp3 to regulate
embryonic vasculogenesis, and to ligate α5β1 and  αvβ3
integrins, we propose that the function of LPP3 protein is
pro-angiogenic. Accordingly, we show that specific inhibi-
tion of LPP3 with an anti-LPP3-RGD polyclonal antibody
inhibit bFGF- and VEGF-induced capillary morphogene-
sis. Currently, a function blocking anti-LPP3 monoclonal
antibody is not available. It is clear that further studies
would be necessary to test the ability and efficiency of var-
ious anti-LPP3 antibodies and peptides to inhibit angio-
genesis in vivo.
Methods
Cells and Reagents
Human umbilical vein endothelial cells (HUVECs) were
purchased from Cambrex Bio Science Inc. (Walkersville,
MD). Media 199, antibiotic solution, L-glutamine and all
other cell culture reagents were purchased from InVitro-
gen Corp. (Carlsbad, CA). Recombinant human vascular
endothelial growth factor (VEGF165), basic fibroblast
growth factor (bFGF), and anti-VEGF (MAB293) were
purchased from R&D Systems Inc. (Minneapolis, MN);
adult human serum-AB from Gemini Bioproducts
(Woodland, CA); bovine skin-derived type I collagen
from Cohesion Technologies, Inc. (Palo Alto, CA). Affin-
ity-purified anti-αvβ3 integrin (LM609), anti-PCNA and
anti-VE-cadherin (MAB1989) monoclonal antibodies
(mAbs) were purchased from Chemicon International
Inc. (Temecula, CA) and anti-KDR/Flk-1 (sc-6251) mAb
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Mouse anti-Fak monoclonal antibody was purchased
Effect of specific antibodies on pre-formed capillaries Figure 4
Effect of specific antibodies on pre-formed capillar-
ies. ECs were cultured in 3D collagen matrices in the pres-
ence of bFGF and VEGF165. Cultures were treated with the 
indicated antibodies at 24 h and processed at various time 
points (indicated). The 3D cultures were fixed, serial sections 
prepared and stained with eosin. The capillaries were 
counted as described in methods section. Values represent 
the mean ± SEM obtained from three independent experi-
ments that used five wells in each case. * P < 0.02.Cell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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from Upstate Biotechnology Inc. (Lake Placid, NY); anti-
human β1 integrin subunit (clone 4B4) mAbs from Beck-
man Coulter Inc. (Fullerton, CA); and anti-MHC class II
(W6/32) from Sigma Chemical Com., (St. Louis, MO).
The preparation of rabbit anti-LPP3-RGD (previously
called anti-VCIP-RGD or anti-PAP2b-RGD) and anti-
LPP3-c-cyto (previously called anti-VCIP-c-cyto or anti-
PAP2b-c-cyto) polyclonal antibodies (pAbs) has been pre-
viously described [23,24].
De-glycosylation of LPP3 protein
Monolayer ECs (2 × 107) at passage 4 were stimulated
with VEGF165 and subjected to cell surface biotinylation as
previously described [23,24]. Biotinylated ECs were solu-
bilized in RIPA cell extraction buffer [50 mM HEPES, pH
7.5, 150 mM NaCl, 1.0% Triton X-100 (non-ionic),
0.25% SDS (anionic), 0.25% sodium deoxycholate
(anionic), and 2 mM EDTA, to which appropriate concen-
trations of proteases were added prior to use]. Extracts
were clarified by centrifugation at 21,000 × g for 45 min
at 4°C. Lysates were pre-absorbed at 4°C for 2 h by incu-
bating with sepharose beads conjugated to rabbit IgGs.
For each immunoprecipitation, approximately 1.5 mg
total protein was used. Immunoprecipitation was carried
out for 3 hr at 4°C. Immunocomplexes were washed five
times with RIPA cell extraction buffer. For deglycosyla-
tion, immunoprecipitates were denatured in 1.0% SDS for
20 min at 90°C and washed twice with deglycosylation
reaction buffer (New England Biolab., Beverly, MA). The
deglycosylation (PNGaseF) reaction was initiated in a
reaction volume of 100 µl containing 0.5% NP40 deter-
gent and 50 units of PNGaseF enzyme at 37°C for 3 h.
Samples were boiled in Lammeli reducing sample buffer
and resolved by 10% SDS-PAGE and transferred to a
nitrocellulose (NC) membrane. The NC membrane was
blocked with 5% milk and 1% BSA in 1× TBS, 0.1% Tween
and analyzed by incubating with streptavidin conjugated
to horse-radish peroxidase (HRP) at a 1:10000 dilution.
For FACS, monolayer ECs were starved for 6 h, thereafter,
either left unstimulated or stimulated with VEGF (100 ng/
Inhibition of bFGF and VEGF induced capillary morphogenesis of ECs in 3D type I collagen matrix Figure 5
Inhibition of bFGF and VEGF induced capillary morphogenesis of ECs in 3D type I collagen matrix. The samples 
shown in the upper panels (A-E) were treated with anti-MHC class II mAbs, whereas those in the lower panels (F-J) with anti-
αvβ3 integrin antibodies. Cross sections were stained with acidified eosin as described in methods. Magnification, 100×. Bar, 
200 µM.Cell Communication and Signaling 2005, 3:9 http://www.biosignaling.com/content/3/1/9
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ml) for 6 h. Cells were then non-enzymatically detached
and subjected to FACS analyses as previously described
[36].
Monolayer and three-dimensional (3D) cell culture
Monolayer EC culture was performed as previously
described [17,18,23,24]. The preparation of 3D collagen
matrix has also been previously described [23,24]. Briefly,
a viscous gel-like solution was prepared by mixing 7 ml of
3.0 mg/ml type I collagen solution with 1 ml of 10× Ml99
medium at 4°C, adjusting the pH to 7.5 with 0.1 N
sodium hydroxide, adding 0.1 ml of 100× ITS, and adjust-
ing to a final volume of 10 ml with sterile distilled water.
The matrix was allowed to polymerize (solidify) for 30
min at 37°C. Next, unstarved proliferating ECs were gen-
tly resuspended (at 6 × 105 cells/ml in complete media),
seeded onto solidified gels, and the dishes (24 well Coster
cell culture dishes) were returned to a CO2 incubator for
2–3 h. At the end of 3 h, unattached cells were removed
by gentle aspiration. Onto monolayer cells, a second layer
of collagen gel was added and returned to a 37°C humid-
ified CO2 incubator. Following solidification (~3 h), the
matrix was layered with Ml99 medium containing 20%
adult human serum-AB, 4 mM L-glutamine, 1× ITS, bFGF
(20 ng/ml) and 100 ng/ml VEGF165. The old growth
medium was removed and fresh medium was added every
24 h. Capillary formation was examined under a phase
contrast microscope every 12 h.
Inhibition Capillary Morphogenesis in 3D culture by anti-
LPP3-RGD antibodies
ECs were embedded in 3D gels as described above, using
media M199. At least 10 random 100× fields were exam-
ined to assess capillary formation (also called tubulogen-
esis). The formation of lumen-like structures was visible
as early as 24 h. Antibodies were dialyzed in sterile dialysis
buffer (25 mM Tris, 175 mM sodium chloride, 2 mM
potassium chloride pH 7.4) overnight and passed through
a 0.22 µM filter prior to use. The integrity of antibodies
was determined by SDS-PAGE. To determine the effects of
specific antibodies on pre-formed capillaries, the method
of Bayless et al. was used [37,38]. Briefly, at the end of 24
h, mAbs (50 µg/ml) and pAbs (75 µg/ml) were added.
Fresh aliquots of antibodies were added every 12 h for a
total of 60 h. To quantify the degree of capillary forma-
tion, 3D matrices were fixed at 24, 36, 48, 60, and 72 h by
aspirating the medium, washing with PBS, and then fixing
with 4% glutaraldehyde in PBS, pH 7.4, overnight at 4°C.
Matrices were then washed with distilled water and
embedded in paraffin according to the manufacturer's
instructions (Richard Allen Scientific, Kalamazoo, MI).
Serial sections (4 µm) were prepared, dehydrated, stained
with acidified eosin, and destained with distilled water.
Capillaries were counted and photographed using a Zeiss
Axiovert 25C microscope at 100× magnification. Each
capillary tubule was surrounded by least 2 to 5 ECs. Cap-
illary formation was defined as the induction of a mini-
mum of 3 separate capillary events within a single field. At
least 10 random fields were counted for each sample.
Experiments were performed in duplicate, using triplicate
wells in each case. Results were expressed as mean ± SEM.
Statistics
Student's t tests and ANOVA were used to detect signifi-
cant comparisons as previously described [23].
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